NCT04883840 (ReMiDy) is a Phase 2, PHASE3 clinical trial of Rosuvastatin 10mg in Ulcerative Colitis, sponsored by Universitaire Ziekenhuizen KU Leuven.

Who is sponsoring NCT04883840?

NCT04883840 is sponsored by Universitaire Ziekenhuizen KU Leuven.

What drugs are being tested in NCT04883840?

Interventions in NCT04883840: Rosuvastatin 10mg.

What condition does NCT04883840 study?

NCT04883840 studies Ulcerative Colitis.

Is NCT04883840 still recruiting?

NCT04883840 is currently terminated. Last updated 25 November 2025.

Last reviewed 2025-11-25 · How we verify

NCT04883840: ReMiDy

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis

Terminated Phase 2, PHASE3 Last updated 25 November 2025

What this trial tests

Phase 2, PHASE3 trial testing Rosuvastatin 10mg in Ulcerative Colitis in 177 participants. Terminated before completion.

Timeline

22 October 2020

Primary endpoint
11 October 2025

11 October 2025

Quick facts

Lead sponsor	Universitaire Ziekenhuizen KU Leuven
Phase	Phase 2, PHASE3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	177
Start date	22 October 2020
Primary completion	11 October 2025
Estimated completion	11 October 2025
Sites	3 locations across Belgium

Drugs / interventions tested

Rosuvastatin 10mg — full drug profile →

Conditions studied

Ulcerative Colitis — all drugs for Ulcerative Colitis →

Sponsor

Universitaire Ziekenhuizen KU Leuven — full company profile →

Who can join

Adults 18 to 70, any sex, with Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* Evaluation of the microbiota modulation away from inflammation associated microbiota profile Bacteroides2 (Bact2) * Evaluation of the effect of microbiota modulation on disease activity in ulcerative colitis and Crohn's disease patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

NLRP3 inflammasome in digestive diseases: From mechanism to therapy.
Qiang R, Li Y, Dai X, Lv W. · · 2022 · cited 23× · PMID 36389791 · DOI 10.3389/fimmu.2022.978190
Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes.
Khan S, Huda B, Bhurka F, Patnaik R, et al · · 2025 · cited 7× · PMID 40943351 · DOI 10.3390/ijms26178429
Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.
Yang X, Guo H, Zou M. · · 2026 · cited 2× · PMID 41495287 · DOI 10.1186/s43556-025-00395-z

Verify or expand the search:

Other trials of Rosuvastatin 10mg

Trials testing the same drug.

NCT06981299 — A Phase 1 Study of PROT-001. · Phase 1 · completed
NCT04903223 — Liver Adiposity Effects on Pediatric Statin · Phase 1 · recruiting
NCT04699279 — Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome · NA · recruiting
NCT04504851 — Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct · Phase 2 · unknown

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

NCT07185009 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07265570 — Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) · Phase 2 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184996 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other Universitaire Ziekenhuizen KU Leuven trials

Trials by the same sponsor.

NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting
NCT07356505 — Efficacy and Safety of Micra AV2 Transcatheter Pacing System · NA · recruiting
NCT07286968 — Gastro-Intestinal Digestion and Physiology After Bariatric Surgery · recruiting
NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04883840 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitaire Ziekenhuizen KU Leuven
Last refreshed: 25 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04883840.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing